MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020.
Read the press release from Medicines and Healthcare products Regulatory Agency published on 16 November 2023.
OpenEdition vous propose de citer ce billet de la manière suivante :
lsgilbert (12 février 2024). MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/vto2





